Literature DB >> 26017316

Management of Small Kidney Cancers in the New Millennium: Contemporary Trends and Outcomes in a Population-Based Cohort.

William C Huang1, Coral L Atoria2, Marc Bjurlin1, Laura C Pinheiro2, Paul Russo3, William T Lowrance4, Elena B Elkin2.   

Abstract

IMPORTANCE: With the significant downward size and stage migration of localized kidney cancers, the management options for small kidney cancers have expanded and evolved.
OBJECTIVE: To describe trends and outcomes in the management of small kidney cancers in the first decade of the new millennium. DESIGN, SETTING, AND PARTICIPANTS: Surveillance, Epidemiology, and End Results (SEER) cancer registry data linked to Medicare claims were used to identify patients 66 years or older with a pathologically confirmed small kidney cancer (<4 cm) diagnosed between January 1, 2001, and December 31, 2009; analysis was performed between February 1, 2014, and December 31, 2014. Multivariable logistic regression was used to assess the likelihood of nonsurgical management vs surgical intervention. Cox proportional hazards regression was used to assess the relationships between treatment approach and overall and cancer-specific survival. The effect of treatment approach on cancer-specific survival was analyzed in a competing risks framework. MAIN OUTCOMES AND MEASURES: The likelihood of receiving no surgery vs surgical intervention as a function of demographic and disease characteristics, as well as the relationships between treatment approach and overall and cancer-specific survival.
RESULTS: Of 6664 patients, 5994 individuals (90.0%) had surgical treatment; the care of 670 patients (10.0%) was managed nonsurgically. Use of radical nephrectomy decreased over time (from 69.0% to 42.5%), and the use of nephron-sparing surgery (partial nephrectomy and ablation) increased (from 21.5% to 49.0%); the proportion of patients who did not undergo surgery remained stable (9.5% and 8.5%). During a median follow-up of 63 months (interquartile range, 43-89 months) (follow-up for vital status through December 31, 2011), 2119 patients (31.8%) patients died, including 293 individuals (4.4%) of kidney cancer. Although overall survival was better in patients who received surgical treatment, only nephron-sparing surgery was associated with a benefit in cancer-specific survival (adjusted hazard ratio, 0.47; 95% CI, 0.31-0.69; P < .001). CONCLUSIONS AND RELEVANCE: Surgery continues to be the most common treatment for patients with small kidney cancers. The use of nephron-sparing surgery exceeds radical nephrectomy in patients who receive surgery. Although our findings suggest that nonsurgical management is acceptable for certain patients, use of this approach remains low.

Entities:  

Mesh:

Year:  2015        PMID: 26017316     DOI: 10.1001/jamasurg.2015.0294

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  16 in total

1.  Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses.

Authors:  Patrick O Richard; Lisa Martin; Luke T Lavallée; Philippe D Violette; Maria Komisarenko; Andrew J Evans; Kunal Jain; Michael A S Jewett; Antonio Finelli
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

Review 2.  Magnetic Resonance Imaging and the Use in Small Renal Masses.

Authors:  M Vedanayagam; B Bhattacharya; S Sriprasad
Journal:  Indian J Surg Oncol       Date:  2016-12-05

Review 3.  Treatment approaches to small renal masses in patients of advanced age (≥75 years).

Authors:  Muhammet Fuat Özcan; Serkan Altınova; Ali Atan
Journal:  Turk J Urol       Date:  2018-07

4.  Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.

Authors:  Adam D Talenfeld; Renee L Gennarelli; Elena B Elkin; Coral L Atoria; Jeremy C Durack; William C Huang; Sharon W Kwan
Journal:  Ann Intern Med       Date:  2018-06-26       Impact factor: 25.391

5.  Robotic-assisted laparoscopic radical nephrectomy using the Da Vinci Si system: how to improve surgeon autonomy. Our step-by-step technique.

Authors:  Hugo H Davila; Raul E Storey; Marc C Rose
Journal:  J Robot Surg       Date:  2016-06-07

6.  Management of high-risk localized kidney cancer: NYU Case of the Month, September 2017.

Authors:  William C Huang
Journal:  Rev Urol       Date:  2017

7.  Use of 3D Printed Models for Complex Renal Surgery: Two Case Presentations: NYU Case of the Month, May 2019.

Authors:  Nicole Wake; William C Huang
Journal:  Rev Urol       Date:  2019

8.  Are the long-term outcomes of percutaneous ablation for clinical stage T1 renal tumors similar to those of partial nephrectomy?

Authors:  Roy Mano; A Ari Hakimi
Journal:  Ann Transl Med       Date:  2019-12

9.  Active surveillance for incidental renal mass in the octogenarian.

Authors:  Kenan E Celtik; Paras H Shah; Vinay R Patel; Daniel M Moreira; Arvin K George; Valerio Iacovelli; Manaf Alom; Andrew Ng; Amin Herati; Simpa S Salami; Hannah Bierwiler; Michael J Schwartz; Lee Richstone; Joph Steckel; Manish A Vira; Louis R Kavoussi
Journal:  World J Urol       Date:  2016-11-01       Impact factor: 4.226

Review 10.  Is percutaneous image-guided renal tumour ablation ready for prime time?

Authors:  Roberto Luigi Cazzato; Julien Garnon; Pierre De Marini; Pierre Auloge; Guillaume Koch; Danoob Dalili; Xavier Buy; Jean Palussiere; Pramod Prabhakar Rao; Thibault Tricard; Hervé Lang; Afshin Gangi
Journal:  Br J Radiol       Date:  2020-06-22       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.